MY196747A - Cell injury inducing therapeutic drug for use in cancer therapy - Google Patents

Cell injury inducing therapeutic drug for use in cancer therapy

Info

Publication number
MY196747A
MY196747A MYPI2018703233A MYPI2018703233A MY196747A MY 196747 A MY196747 A MY 196747A MY PI2018703233 A MYPI2018703233 A MY PI2018703233A MY PI2018703233 A MYPI2018703233 A MY PI2018703233A MY 196747 A MY196747 A MY 196747A
Authority
MY
Malaysia
Prior art keywords
cancer therapy
therapeutic drug
cell injury
inducing therapeutic
domain
Prior art date
Application number
MYPI2018703233A
Other languages
English (en)
Inventor
Yasuko Kinoshita
Yumiko Kawai
Toshiaki Tsunenari
Takahiro Ishiguro
Mika Endo
Yuji Sano
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MY196747A publication Critical patent/MY196747A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2018703233A 2016-03-14 2017-02-24 Cell injury inducing therapeutic drug for use in cancer therapy MY196747A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016050095 2016-03-14
PCT/JP2017/007033 WO2017159287A1 (ja) 2016-03-14 2017-02-24 癌の治療に用いるための細胞傷害誘導治療剤

Publications (1)

Publication Number Publication Date
MY196747A true MY196747A (en) 2023-05-03

Family

ID=59851601

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018703233A MY196747A (en) 2016-03-14 2017-02-24 Cell injury inducing therapeutic drug for use in cancer therapy

Country Status (15)

Country Link
US (3) US11072666B2 (https=)
EP (1) EP3431102A4 (https=)
JP (4) JP6175590B1 (https=)
KR (2) KR20180116215A (https=)
CN (2) CN109069640B (https=)
AU (2) AU2017233658B2 (https=)
BR (1) BR112018068363A2 (https=)
CA (1) CA3016424A1 (https=)
MX (2) MX2018010988A (https=)
MY (1) MY196747A (https=)
PH (1) PH12018501977A1 (https=)
RU (1) RU2746754C2 (https=)
SG (2) SG10202007025PA (https=)
TW (3) TW202342540A (https=)
WO (1) WO2017159287A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
AU2015244814B2 (en) 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
WO2017086367A1 (ja) * 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
TW201834688A (zh) 2017-02-24 2018-10-01 日商中外製藥股份有限公司 藥學組成物、抗原結合分子、治療方法以及篩選方法
EP3753956A4 (en) * 2018-02-14 2021-12-22 Chugai Seiyaku Kabushiki Kaisha ANTIGIBONDING MOLECULE AND COMBINATION
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
WO2020153467A1 (ja) * 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
JP7392145B2 (ja) 2019-12-20 2023-12-05 山東博安生物技術股▲ふん▼有限公司 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム
US20230057939A1 (en) * 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
MX2022013920A (es) * 2020-05-07 2022-11-30 Phanes Therapeutics Inc Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
MX2022015764A (es) * 2020-06-19 2023-01-19 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis.
WO2022002112A1 (en) * 2020-07-01 2022-01-06 Shandong Boan Biotechnology Co., Ltd. Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody
CN114524878B (zh) * 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CA3205422A1 (en) * 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
WO2023045151A1 (en) * 2021-09-24 2023-03-30 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against gpc3 and uses thereof
CN116355097B (zh) * 2021-09-24 2023-11-14 浙江时迈药业有限公司 针对gpc3的抗体及其用途和组合物
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
CN120051491A (zh) * 2022-11-01 2025-05-27 上海齐鲁制药研究中心有限公司 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
AR132344A1 (es) * 2023-04-10 2025-06-18 Medimmune Llc Optimización de los dominios de unión al antígeno cd3
CN116949156B (zh) * 2023-09-19 2023-12-08 美迪西普亚医药科技(上海)有限公司 一种基于核酸变体的通用型检测人t细胞的分析方法

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
CS269411B1 (en) 1988-09-14 1990-04-11 Ales Manek Device for yearn's interruption
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
PT812136E (pt) 1995-02-28 2001-04-30 Procter & Gamble Preparacao de bebidas nao gaseificadas com estabilidade microbiana superior
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
WO2000018806A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
PL366025A1 (pl) 2000-05-03 2005-01-24 Munich Biotech Ag Kationowe środki diagnostyczne, obrazujące i terapeutyczne, zasocjowane z uaktywnionymi miejscami wnaczyniach
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
DE60236735D1 (de) 2001-04-13 2010-07-29 Biogen Idec Inc Antikörper gegen vla-1
KR100953520B1 (ko) 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
WO2003068801A2 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
EP1697748A4 (en) 2003-12-22 2007-07-04 Centocor Inc METHODS FOR GENERATING MULTIMEDIA MOLECULES
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CA2572133A1 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
SI1674111T1 (sl) 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
JP5224580B2 (ja) 2005-06-10 2013-07-03 中外製薬株式会社 ｓｃ（Ｆｖ）２部位特異的変異体
WO2006132352A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2433650A3 (en) 2006-06-06 2012-12-19 Tolerrx Inc. Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20110236374A1 (en) 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
ME02345B (me) 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
US8497355B2 (en) 2007-09-28 2013-07-30 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102164960A (zh) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
AU2009303318B2 (en) 2008-10-10 2016-06-30 Aptevo Research And Development Llc TCR complex immunotherapeutics
DE202008016028U1 (de) 2008-12-04 2010-04-15 Melitta Haushaltsprodukte Gmbh & Co. Kg Behälter zur Aufbewahrung von Gegenständen
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
BR112012004546A8 (pt) * 2009-08-29 2017-12-05 Abbott Lab Terapêutica por proteínas ligantes dll4-ligantes
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
CA2785414C (en) 2009-12-25 2019-01-22 Tomoyuki Igawa Polypeptide modification method for purifying polypeptide multimers
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
WO2012093704A1 (ja) 2011-01-07 2012-07-12 中外製薬株式会社 抗体の物性を改善させる方法
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
JP6509724B2 (ja) 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
SG11201407972RA (en) 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
IN2015DN01299A (https=) 2012-07-23 2015-07-03 Zymeworks Inc
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
EP2914634B1 (en) 2012-11-02 2017-12-06 Zymeworks Inc. Crystal structures of heterodimeric fc domains
CN103833852A (zh) 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
AU2015244814B2 (en) * 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6837436B2 (ja) 2015-07-10 2021-03-03 中外製薬株式会社 内因性ｃｄ３遺伝子をヒトｃｄ３遺伝子に置換した非ヒト動物
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
UA130542C2 (uk) 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта

Also Published As

Publication number Publication date
RU2746754C2 (ru) 2021-04-20
SG11201807936VA (en) 2018-10-30
KR101834708B1 (ko) 2018-03-06
US20250066503A1 (en) 2025-02-27
TW202214700A (zh) 2022-04-16
WO2017159287A1 (ja) 2017-09-21
JP6175590B1 (ja) 2017-08-02
TW202342540A (zh) 2023-11-01
AU2023266341A1 (en) 2023-12-07
US20210388110A1 (en) 2021-12-16
SG10202007025PA (en) 2020-08-28
US20200048361A1 (en) 2020-02-13
BR112018068363A2 (pt) 2019-01-15
US11072666B2 (en) 2021-07-27
AU2017233658A1 (en) 2018-09-13
TW201735947A (zh) 2017-10-16
EP3431102A4 (en) 2019-09-25
RU2018135317A (ru) 2020-04-15
JPWO2017159287A1 (ja) 2018-03-22
JP2024054340A (ja) 2024-04-16
PH12018501977A1 (en) 2019-06-17
CN109069640B (zh) 2023-10-03
CN117205314A (zh) 2023-12-12
AU2017233658B2 (en) 2023-09-21
JP2022116257A (ja) 2022-08-09
JP2017214405A (ja) 2017-12-07
CN109069640A (zh) 2018-12-21
MX2018010988A (es) 2019-01-21
MX2023005645A (es) 2023-05-25
JP7440569B2 (ja) 2024-02-28
CA3016424A1 (en) 2017-09-21
KR20180116215A (ko) 2018-10-24
EP3431102A1 (en) 2019-01-23
RU2018135317A3 (https=) 2020-06-29

Similar Documents

Publication Publication Date Title
MY196747A (en) Cell injury inducing therapeutic drug for use in cancer therapy
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12018500285A1 (en) Bridge linkers for conjugation of a cell-binding molecule
PH12018502429A1 (en) Antibody molecules for cancer treatment
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
NZ737471A (en) Hydrophilic linkers for conjugation
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2023008849A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
FR3096259B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie